MARKET

CNTA

CNTA

Centessa Pharmaceuticals Plc
NASDAQ
24.85
-0.13
-0.52%
After Hours: 24.36 -0.49 -1.97% 16:24 12/18 EST
OPEN
25.32
PREV CLOSE
24.98
HIGH
25.50
LOW
24.43
VOLUME
1.49M
TURNOVER
--
52 WEEK HIGH
30.58
52 WEEK LOW
9.60
MARKET CAP
3.63B
P/E (TTM)
-13.6202
1D
5D
1M
3M
1Y
5Y
1D
Wells Fargo Keeps Their Buy Rating on Centessa Pharmaceuticals (CNTA)
TipRanks · 13h ago
Weekly Report: what happened at CNTA last week (1208-1212)?
Weekly Report · 3d ago
Centessa Pharmaceuticals (CNTA): Assessing Valuation After New CEO Appointment and Refined Orexin-Focused Strategy
Simply Wall St · 3d ago
These 3 Unknown Stocks Can Double, Say Five-Star Analysts – 12/11/2025
TipRanks · 12/11 22:50
Centessa falls -8.4%
TipRanks · 12/11 15:05
Centessa Pharmaceuticals CEO Saurabh Saha To Step Down; Mario Accardi Named Replacement
NASDAQ · 12/11 13:47
Centessa Pharmaceuticals Appoints New CEO Amid Strategic Shift
TipRanks · 12/11 13:18
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Regeneron (REGN) and Elicio Therapeutics (ELTX)
TipRanks · 12/11 13:10
More
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

Webull offers Centessa Pharmaceuticals PLC - ADR stock information, including NASDAQ: CNTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTA stock methods without spending real money on the virtual paper trading platform.